The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension.
There were investigated 22 patients with chronic obstructive pulmonary disease in association with arterial hypertension initially and after 5 weeks of treatment with beta-blocker Nebivolol 5 mg/day. There were not detected any negative changes on bronchial permeability after treatment. Considerable improvement of endothelial function (from 7-12% to 17-35%, p < 0.05) in parallel with decreasing of pulmonary artery, systolic (44.5 +/- 5.5 mmHg vs. 32.8 +/- 4.1 mmHg, p < 0.05) and mean pressure (26.3 +/- 4.2 mmHg vs. 21.1 +/- 2.1 mmHg, p < 0.05)--were observed after treatment. Thus, Nebilet is well-tolerated and highly effective in patients with chronic obstructive pulmonary disease in association with arterial hypertension.
IMSP Institute of Phtisiopneumology "Chiril Draganiuc" Chishinau.
C
C
Martiniuc
T
T
Branishte
D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001578:Benzopyrans / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects*; D004983:Ethanolamines / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013147:Spirometry; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
D058671:Adrenergic beta-1 Receptor Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol